The study by Probstifield [13], applied CGMS to 102 T2DM patients with high cardiovascular risk to determine blood fluctuation in patients received basal insulin with twice-daily Exenatide or with bolus insulin after 26 weeks. The gene discussed is INS; the disease is type 2 diabetes mellitus.